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ABSTRACT 
A selective method for separation and determination of potential related impurities (starting materials and by-products of synthesis, and 
degradants) of apremilast drug substance has been developed and validated. The separation was accomplished on a Cosmosil C-18 (250 mm × 
4.6 mm, 5 μm) column connected to a photodiode array (PDA) detector using optimized mixture of 0.05% trifluoroacetic acid, me thanol and 
acetonitrile under gradient elution. Two major degradant impurities found in force degradation study of apremilast drug substance. Both 
degradants were characterized preliminarily by HPLC-MS studies and synthesized in laboratory. Structure was evidenced by NMR 
spectroscopy, mass spectrometry and HPLC method was developed for quantification of the synthesized impurities along with starting 
materials. This method can be used for the quality control testing of drug substance. The performance of the method was validated according to 
the ICH guide lines for specificity, limit of detection, limit of quantification, linearity, accuracy, precision, ruggedness and robustness.  
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Apremilast is chemically known as N-[2-[(1S)-1-(3-ethoxy-4-
methoxyphenyl) -2 (methylsulfonyl)ethyl]-1,3-dioxo-2,3- 
dihydro-1H-isoindol-4-yl]acetamide. It has an empirical 
formula of C22H24N2O7S, and a molecular weight of 460.5 g 
mole−1. 
Apremilast is a Food and Drug Administration approved 
drug used for treatment of psoriasis and psoriatic arthritis. It 
may also be useful for other immune system related 
inflammatory diseases. The drug acts as a selective inhibitor 
of the enzyme phosphodiesterase 4 (PDE4) and inhibits 
spontaneous production of TNF-alpha from human 
rheumatoid synovial cells [1, 2, 3]. The US-FDA approved 
Apremilast for the treatment of moderate to severe plaque 
psoriasis. It is also being tested for its efficacy in treating 
other chronic inflammatory diseases such asankylosing 
spondylitis, Behcet's disease, and rheumatoid arthritis [4,5]. 
Several research papers have been reported in the literature 
for the determination of apremilast. These papers were 
limited to the assay of apremilast alone performed by UV 
spectrophotometry where impurity identification and 
quantification is not done [6]. New related impurities are 
synthesized and quantification method with HPLC is 
reported but the obvious degradants which studied here in 
present research are not reported [7]. Pharmacokinetic 
study of apremilast in rat plasma has been studied by using 
UPLC MS/MS where apremilast is quantified in the blood 
plasma [8, 9]. The reported related substance methods are 
suitable for quantification of some of related impurities but 
another degradants formed under the stress conditions 
employed were neither discussed nor characterized. Further, 
no monograph of apremilast is published in any of the 
pharmacopoeia for 
compendia applications. In present research during force 
degradation study two major degradant impurities were 
observed when the drug substance is exposed to acid and 
base degradation. Both degradants were synthesized in 
laboratory and structure is elucidated using LCMS, 1H NMR 
and IR spectroscopy techniques. The RP-HPLC method is 
developed for the separation and determination of 
apremilast and potential related impurities i.e. raw materials, 
by-products and degradants. The proposed analytical 
method is validated as per International conference on 
harmonization guidelines (ICH Q2-R1) [10, 11, 12]. The 
manuscript describes a comprehensive investigation on 
isolation and characterization of a major process related 
impurities of Apremilast 3-(acetylamino -2-{[1-(3-ethoxy-4- 
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methoxyphenyl)-2 (methylsulfonyl)ethyl]carbamoyl}benzoic 
acid i.e. Impurity-B and 3-(acetylamino-6-{[1-(3-ethoxy-4. 
Apremilast, brand name Otezla among others, is a 
medication for the treatment of certain types of psoriasis and 
psoriatic arthritis. It may also be useful for other immune 
system related inflammatory diseases. The drug acts as a 
selective inhibitor of the enzyme phosphodiesterase 4 
(PDE4) and inhibits spontaneous production of TNF-alpha 
from human rheumatoid synovial cells. 
 
Mechanism of action 
Apremilast is a small molecule inhibitor of PDE4,[13] an 
enzyme that breaks down cyclic adenosine monophosphate 
(cAMP). In inflammatory cells, PDE4 is the dominant enzyme 
responsible for this reaction. The resulting increase in cAMP 
levels down-regulates expression of a number of pro-
inflammatory factors like tumor necrosis factor alpha 
(TNFα), interleukin 17, interleukin 23, and many others, and 
up-regulates the anti-inflammatory interleukin 10. In ex vivo 
models of arthritis, IL-12/IL-23p40 was specifically 
identified as a downstream target of apremilast[14] The 
importance of these individual factors for the clinical effect of 
apremilast is not clear 
Pharmacokinetics 
Apremilast is absorbed from the gut well (73%) and 
independently of food intake, and reaches peak blood plasma 
concentrations after 2.5 hours. Plasma protein binding is 
68%. It is metabolised in the liver, mainly via the enzyme 
CYP3A4, but to a minor extent via CYP1A2 and CYP2A6. The 
main metabolite is O-desmethylapremilast glucuronide.[15]  
The half-life is 6–9 hours. The substance is eliminated 
through the kidney (58%) and feces (39%), mainly in form of 
its metabolites. Only 3% of the original substance are found 
in the urine, and 7% in the feces. 
Particle size, polydispersity index (PDI), and zeta 
potential (ZP)  
The developed APM-loaded PLGA NPs were freeze dried 
followed by dispersing them in the Milli-Q water (20 μg/mL). 
The suspension was then characterized for particle size, 
polydispersity index (PDI), and zeta potential (ZP) using the 
dynamic light-scattering technique. The Malvern Particle Size 
Analyzer (Malvern Instruments Ltd, Holtsville, NY, USA) was 
used to measure the mean particle size and the PDI of 
different developed NPs (F1–F3). The NP samples were 
diluted to 200 times with deionized water and sonicated for 
10 minutes in order to obtain clear aqueous dispersion. Each 
sample (3 mL) was The supernatant of the sample was 
withdrawn at different time intervals (1, 2, 3, 4, 5, 6, 12, 24, 
and 48 hours). The collected sample was centrifuged at 
12,000 rpm for 5 minutes and analyzed for the drug content 
using UV spectroscopy at 229 nm[16] The data obtained 
from the release study were plotted and fitted in various 
kinetic models to obtain the release pattern of the drug from 
the polymeric matrix. in transparent disposable plastic 
cuvettes and the mean particle size and PDI were measured. 
The same analyzer was utilized to measure the ZP of the NPs 
(F1–F3) but the measurements were done using glass 
electrode. 
ANALYTICAL METHOD VALIDATION 
Method validation is closely related to method development. 
When a new method is being developed, some parameters 
are already being evaluated during the “development stage,” 
while in fact, this forms part of the “validation stage.” Related 
substances method is validated as per ICH guideline [9]. 
Specificity and force degradation 
The ability of the method to determine accurately and 
specifically the analyte of interest in the presence of other 
components in a sample matrix that may be expected to be 
present in the sample matrix under the stated conditions. 
Specificity of the method was evidenced by comparing blank, 
apremilast and all specified impurities separate injections as 
well as spiking all impurities into apremilast test solution. 
Force degradation study is performed by exposing the 
sample to heat at 105⁰C for 24 hours, sample treated with 
base 1 N sodium hydroxide and with acid 1N hydrochloric 
acid. Sample was exposed to ultra-violet light for 24 hours 
and 3% hydrogen peroxide solution. After exposure samples 
were tested using the proposed related substances method 
with photo diode array detector. The degraded samples were 
further analyzed to find out assay of apremilast. Mass 
balance is calculated by comparison of total impurities from 
related substances test and the assay of apremilast. 
Solution stability 
Drug stability in Active Pharmaceutical Ingredient is a 
function of storage conditions and chemical properties of the 
drug and its impurities. Conditions used in stability 
experiments should reflect situations likely to be 
encountered during actual sample handling and analysis. 
Stability data are required to show that the concentration 
and purity of analyte in the sample at the time of analysis 
corresponds to the concentration and purity of analyte at the 
time of sampling. The solution stability till twelve hours of 
apremilast API had been checked by injecting test solution 
and standard solution. Test solution was prepared fresh 
before injection and immediately injected and same solution 
was injected after twelve hours. 
Linearity 
The ability of the method to obtain test results proportional 
to the concentration of the analyte within a given range. It 
was evaluated by linear regression analysis, which was 
calculated by the least square regression method. 
Limit of detection 
The limit of detection (LOD) is the lowest concentration of 
analyte in a sample that can be detected but not necessary 
quantified. The obtained LOD values of specified impurities 
and API is discussed. 
LOD = 3.3 × σ / S 
Where, σ = the standard deviation of the response and 
 S= slope of the calibration curve 
Limit of quantitation 
The limit of quantitation is the lowest concentration or 
amount of analyte that can be determined quantitatively 
within an acceptable level of repeatability precision and 
trueness. 
Limit of quantitation (LOQ) = 10.0 × σ / S 
Where, σ = the standard deviation of the response and 
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Precision at LOQ is confirmed by six replicate analyses of 
impurities at LOQ level. 
Accuracy 
Accuracy can be defined as the closeness of agreement 
between a test result and the accepted reference value. 
Accuracy of the method was determined by recovery study. 
Analytical method may be considered validated in terms of 
accuracy if the mean value is within ± 20% of the actual 
value. During recovery study apremilast API batch was 
analyzed and then all specified impurities of known 
concentration is spiked in the API at LOQ level, 50%, 100% 
and 150% with respect to the limit of specified impurity. 
Ruggedness 
The (intra-laboratory tested) behavior of an analytical 
process when small changes in environment and/or 
operating condition are made. The ruggedness of the method 
was evaluated by estimating % RSD of standard solution 
tested by two different analysts using different HPLC 
instrument and columns on different days. Three validation 
batches were prepared by each analyst separately. % RSD of 
each impurity of preparations of both analysts should not be 
more than 10%. 
Robustness 
Robustness is a measure of the capacity of the analytical 
procedure to remain unaffected by small but deliberate 
variations in method–performance parameters, which 
provides an indication of its reliability during normal usage. 
Robustness of the method was determined by analyzing the 
system suitability solution and batch analysis with deliberate 
change in the parameters like (a) flow rate of mobile phase ± 
0.1ml/min and (b) column temperature ± 5°C. 
Bioanalytical methods  
An ultraperformance liquid chromatography coupled with 
tandem mass spectrometry (MS/MS) was used for the quan-
tification of APM in rat plasma samples. Our previously 
reported assay was modified for this purpose.[17] To 
increase the sensitivity of the assay, the electrospray 
ionization was operated in positive mode and the calibration 
range was between 1 and 1,000 ng/mL with lower limit of 
quantification of 1 ng/mL in plasma samples. Due to change 
in the ionization mode, losartan was used as the internal 
standard (IS). The precursor to product ion transition of 
461.16 &178.08 and 423.13 207.12 was used for detection 
and quantification of analyte (APM) and the IS (losartan), 
respectively, in the multiple reaction monitoring (MRM) 
mode. The optimized MS/MS parameters of capillary voltage 
4.00 kV, source temperature 150°C, desolvation temperature 
350°C, and collision gas flow rate 0.17 mL/minute were used 
for sample ionization. A cone voltage of 26 V (both for 
analyte and IS) and collision energy of 28 and 20 eV were 
used for the analyte and the IS, respectively, as compound-
specific parameters. Due to change in ionization mode and IS, 
the assay was partially validated in terms of precision and 
accuracy following the US Food and Drug Administration 
2013 guideline for bioanalytical method validation. Both 
intra- and interday variation in precision and accuracy was 
found to be within the acceptable limits of ±15%. 
Adverse effects 
Diarrhea and vomiting 
Diarrhea occurs in about 25% of patients taking apremilast. 
Severe gastrointestinal symptoms, when they occur, typically 
start within the first few weeks of treatment.[18,19] 
Psychological 
Worsening depression, suicidal thoughts, and other mood 
changes may occur with apremilast.[20]  
Weight loss 
Weight loss: Weight loss has been associated with 
apremilast. Reports from clinical studies indicated a 5 to 
10% decrease in body weight in 10% of patients taking 
apremilast (compared to 3.3% of patients taking 
placebo).[20] 
Other 
Common, usually mild to moderate adverse effects 
associated with apremilast include headache, back pain, 
nausea, diarrhea, fatigue, nasopharyngitis and upper 
respiratory tract infections.[21] 
CONCLUSION 
Process related impurities of apremilast are identified, 
synthesized and characterized. Structural elucidations of all 
synthesized compounds were done by using NMR, IR and 
mass spectral data. Impurity of RRT 0.77 is 3-(acetylamino-
2- {[1-(3-ethoxy- 4-methoxyphenyl) -2-(methylsulfonyl) 
ethyl]carbamoyl} benzoicacid i.e. Impurity-B. Impurity at 
RRT 0.79 is 3- (acetylamino-6-{[1-(3-ethoxy-4- 
methoxyphenyl)-2-(methylsulfonyl) ethyl] carbamoyl} 
benzoicacid i.e. Impurity-C. All process related impurities 
and degradant impurities are quantified in the proposed 
method of analysis. Thus, the regulatory requirement was 
fulfilled by characterizing this impurity and the prepared 
impurity standard was used during analytical method 
validation studies. The above RP-HPLC analytical method 
satisfies all validation parameters like system suitability, 
precision, specificity, accuracy, linearity of detector 
response, ruggedness and robustness. At the same time the 
method satisfies the forced degradation study. It indicates 
that the method is stable and suitable for the apremilast and 
its related substances determination. Hence, the validated 
method can be used for routine analysis of related 
substances in apremilast in quality control laboratories in 
the pharmaceutical industry. 
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